Background: The underlying mechanisms for the development of albuminuria and the increased cardiovascular risk in patients with elevated albuminuria levels are incompletely understood. We therefore investigated the associations between 80 cardiovascular proteins and the urinary albumin to creatinine ratio (ACR). Methods: We used a discovery/replication approach in two independent community-based cohorts of elderly patients: the Uppsala Longitudinal Study of Adult Men (n ¼ 662; mean age 78 years) and the Prospective Investigation of the Vasculature in Uppsala Seniors (n ¼ 757; mean age 75 years; 51% women). A proteomic chip with a panel of 80 plasma proteins associated with different aspects of cardiovascular disease was analysed. In the discovery cohort, we used a false discovery rate of 5% to take into account the multiple statistical testing. Nominal p values were used in the replication. Results: Higher levels of T-cell immunoglobulin mucin-1, placenta growth factor, growth/differentiation factor-15, urokinase plasminogen activator surface receptor and kallikrein-11 were robustly associated with a higher ACR in both cohorts in multivariable linear regression models adjusted for sex, established cardiovascular risk factors, antihypertensive treatment, prevalent cardiovascular disease and glomerular filtration rate (p < 0.02 for all). All associations were also significant in separate analyses of patients without diabetes. Conclusions: We discovered and replicated associations between ACR and five cardiovascular proteins involved in tubular injury, atherosclerosis, endothelial function, heart failure, inflammation, glomerulosclerosis and podocyte injury. Our findings put forward multiplex proteomics as a promising approach to explore novel aspects of the complex detrimental interplay between kidney function and the cardiovascular system.
Introduction
Low grade albuminuria (or micro-albuminuria) has been assessed for decades in clinical diabetes management 1 as an early indicator of diabetic nephropathy, 2 but is also used for risk prediction in patients with hypertension and chronic kidney disease. 3 Albuminuria has also been shown to be an independent risk factor for future cardiovascular events and mortality in the community, even in people without hypertension or diabetes. [4] [5] [6] In a recent meta-analysis of individual level data on over 600,000 participants and more than 10,000 cardiovascular deaths, 7 the urinary albumin to creatinine ratio (ACR) was the single strongest cardiovascular risk factor for cardiovascular mortality, adding significant prognostic improvement beyond established cardiovascular risk factors. 7 The level of albuminuria has also been proposed as a marker of early vascular disease, 8 mirroring the severity and duration of high blood pressure, diminished endothelial function and the risk of retinopathy. 8, 9 Despite its widespread use in clinical practice, however, the underlying mechanisms for the development of albuminuria and the increased cardiovascular risk seen in patients with elevated levels of albuminuria are still incompletely understood.
Recent technological advances have enabled the simultaneous measurement of multiple proteins. 10 It is possible to simultaneously measure 92 proteins selected to be important in cardiovascular disease using a custommade proteomics chip based on the proximity extension assay technology. 11 Given the close interplay between albuminuria and the development of cardiovascular disease, we hypothesized that these cardiovascular biomarkers would be of interest for both the underlying renal and cardiovascular pathology reflected by elevated albuminuria levels. We aimed to explore these associations using a proteomic chip with an assay panel of 92 proteins involved in cardiovascular disease and the ACR in a cohort of elderly men and to validate the findings in a second cohort of both men and women.
Methods

Uppsala Longitudinal Study of Adult Men
The Uppsala Longitudinal Study of Adult Men (ULSAM) study was initiated in 1970. All 50-year-old men born in 1920-1924 and living in Uppsala, Sweden were invited to a health survey focusing on identifying cardiovascular risk factors (described in detail at www. pubcare.uu.se/ULSAM). 12 The present study used the fourth examination cycle as the baseline, when the participants were about 77 years old (1998) (1999) (2000) (2001) . Of the 1398 invited men, 838 (60%) participated and data on the proteomics chip were available in 786 participants. After the exclusion of participants without data on their ACR, the present study sample consisted of 662 participants.
Prospective Investigation of the Vasculature in Uppsala Seniors
All 70-year old men and women living in Uppsala, Sweden between 2001 and 2004 were eligible for the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS study) (described in detail at www.medsci.uu.se/pivus/pivus.htm). 13 Of the 2025 invited participants, 1016 agreed to the study. The proteomics chip was analysed in samples from this investigation, but no data was collected on albuminuria. A second examination cycle of PIVUS was performed in 2006-2009 when the participants were 75 years old. Of 964 invited participants, 827 (86%) agreed to the study. At this examination, 757 participants had valid measurements of ACR and thus comprised the present study sample.
All participants in PIVUS and ULSAM gave written informed consent and the ethics committee of Uppsala University approved the study protocols. Both studies were conducted according to the Declaration of Helsinki.
Baseline and follow-up investigations
The investigations in PIVUS and ULSAM were performed using similar standardized methods, including anthropometric measurements, blood pressure, blood sampling and questionnaires regarding socioeconomic status, medical history, smoking habits, medication and levels of physical activity. 12, 13 Venous blood samples were drawn in the morning after an overnight fast and stored at À70 C until analysis; the mean storage time in ULSAM was 14.1 years (range 13.0-16.4 years) and in PIVUS 11.6 years (range 10.0-13.3 years). Diabetes mellitus was diagnosed as a fasting plasma glucose level ! 7.0 mmol/l (!126 mg/dl) or the use of antidiabetic drugs.
14 Cystatin C, measured by a latex-enhanced reagent (NLatexCystatin C; Siemens, Deerfield, IL, USA) using a BN ProSpec analyser (Siemens) in ULSAM 15 and by latex-enhanced reagents (Gentian, Moss, Norway) using an Architect ci8200 (Abbott Laboratories, Abbott Park, IL, USA) in PIVUS was used to estimate the glomerular filtration rate (GFR). 15, 16 In ULSAM, a 24-h urine sample was collected and stored at À70 C until analysis. Morning spot urine was collected at the re-examination at age 75 years in PIVUS. Urine albumin was measured by nephelometry (Dade Behring, Deerfield, IL, USA) using a Behring BN ProSpec analyser (Dade Behring). Urinary creatinine was determined with a modified kinetic Jaffe reaction on an Architect Ci8200 analyser (Abbott, Abbot Park, IL, USA) and the ACR was calculated. Prevalent cardiovascular disease was defined as admission to hospital for either myocardial infarction (ICD-10 code I21), stroke (I61, I63-66) or heart failure (I50, I11, I13) prior to the baseline examination based on data from the Swedish Hospital Discharge Register.
Proseek Multiplex Cardiovascular Disease panel
The Olink Proseek Multiplex Cardiovascular 96X96 kit was used to measure proteins in plasma by real-time polymerase chain reaction using the Fluidigm BioMark HD real-time polymerase chain reaction platform as reported previously. 10, 11 Of the 96 wells, one was a negative control and three were positive controls (spiked with interleukin 6 (IL-6), IL-8 and vascular endothelial growth factor A (VEGF-A)), resulting in 92 measured proteins. Each sample included two incubations, one extension and one detection control used to determine the lower detection limit and to normalize the measurements. The resulting relative values obtained were log 2 -transformed for subsequent analysis.
Twelve proteins with a call rate <85% (i.e. <85% of the participants had a valid measurement of that protein in either cohort) were removed from further analysis, including IL-4, melusin, Brain natriuretic peptide (BNP), Beta-nerve growth factor (Beta-NGF), SIR2-like protein 2 (SIRT2), NF-kappa-B essential modulator (NEMO), Membrane-bound aminopeptidase P (mAmP), Pentraxin-related protein 3 (PTX3), N-terminal pro-B-type natriuretic peptide (NT-pro-BNP), Matrix metalloproteinase-7 (MMP-7), Heat shock 27 kDa protein (HSP 27) and Cystatin-B (CSTB). Hence 80 proteins were taken forward for analysis. Participants with excess missingness based on a histogram were excluded (>5% missing protein values in PIVUS and >2% in ULSAM). Values below the lower limit of detection (LOD) were replaced by LOD/2. Each protein was normalized by plate (by setting the mean ¼ 0 and standard deviation ¼ 1 within each plate) and further by storage time (correction based on the observed values and predicted values from a spline model).
Statistical analysis
For the primary analysis, ULSAM was used as the discovery sample and PIVUS for replication. 17 For discovery, linear regression models were performed for each of the 80 proteins in separate models with adjustments for age, GFR, low-and high-density lipoprotein cholesterol, systolic blood pressure, body mass index, diabetes, smoking, prevalent cardiovascular disease and antihypertensive drugs (angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, calcium antagonists, thiazide diuretics and b blockers).
We adjusted the models for all these established cardiovascular risk factors to isolate the novel aspects mirrored by the cardiovascular proteins. The proteins showing a false discovery rate <5% were taken further to linear regression analyses in the replication sample, adjusting for the same factors and also sex. Sub-group analyses were made in participants without diabetes with a GFR > 60 ml/min/1.73 m 2 or without prevalent cardiovascular disease at baseline. A nominal p value of <0.05 for the multiple-adjusted analysis was considered as a valid replication in PIVUS. STATA 12 was used for calculations (Stata, College Station, TX, USA).
Results
Baseline characteristics for the covariates in ULSAM and PIVUS are shown in Table 1 . Using a false discovery rate of 5% (corresponding to p < 0.015), a total of 26 proteins were significantly associated with ACR after adjustments for GFR, established cardiovascular risk factors, prevalent cardiovascular disease and treatment with antihypertensive drugs in the ULSAM cohort ( Figure 1 ). Of these 26 proteins, five were replicated in the PIVUS cohort in the same multivariable model (in order of significance: T-cell immunoglobulin mucin 1 (TIM-1), placenta growth factor (PlGF), Figure 1 . Linear regression models were adjusted for age, glomerular filtration rate, low-density lipoprotein and high-density lipoprotein cholesterol, systolic blood pressure, body mass index, diabetes, prevalent cardiovascular disease, smoking and antihypertensive drugs (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium antagonists, thiazide diuretics and b blockers) in the ULSAM cohort .
growth/differentiation factor 15 (GDF-15), kallikrein-11 (hK11) and urokinase plasminogen activator surface receptor (U-PAR); Figure 2 ). The association between all proteins and ACR in PIVUS is given in Supplementary Figure 1 , available online).
In the stratified analyses, all five proteins were significantly associated with ACR in both ULSAM and PIVUS when participants without diabetes or without prevalent cardiovascular disease were analysed separately. PlGF, GDF and TIM-1 were significant in both cohorts when participants with normal kidney function (GFR > 60 ml/min/1.73 m 2 ) were analysed separately ( Figure 2 ).
Discussion
We explored and validated the associations between 80 plasma proteins involved in cardiovascular pathology and urinary ACR in two community-based cohorts of elderly patients. Five proteins involved in tubular injury, atherosclerosis, endothelial function, heart failure, inflammation, glomerulosclerosis and podocyte injury (TIM-1, PlGF, GDF-15, U-PAR and hK11) were significantly associated with ACR in both cohorts after adjustments for age, sex, established cardiovascular disease risk factors, antihypertensive drugs, prevalent cardiovascular disease and kidney function. Most of these proteins were significantly associated with ACR in separate analyses in participants without diabetes, with normal kidney function or without prevalent cardiovascular disease. The association with ACR has not been reported previously for TIM-1 and hK11. TIM-1 is also known as kidney injury molecule-1 (KIM-1) and is excreted in urine. Urinary levels of TIM-1 (KIM-1) is a well-established marker for acute kidney damage. [18] [19] [20] However, what the plasma levels of TIM-1 actually reflect has been less well studied. We previously reported that circulating TIM-1 was associated with the number of carotid arteries affected by atherosclerotic plaques. 11 In addition to being involved in acute kidney damage, previous experimental studies have suggested that TIM-1 is active in the regulation of T helper cell immune responses, 21 a mechanism that plays an important part in the development of atherosclerosis. 22 Because the association between plasma TIM-1 and albuminuria was stronger than the association with any of the other 80 proteins investigated, our findings warrant additional studies to better understand the role of circulating TIM-1 in the development of both cardiovascular and kidney disease.
PlGF is a member of the vascular endothelial growth factor (VEGF) family that induces the proliferation of vascular smooth muscle cells, monocyte chemotaxis, plaque inflammation and plaque instability. [23] [24] [25] Both VEGF and PlGF have been shown to increase vascular permeability, 26 which could explain the association with albuminuria in this study. PlGF levels have been shown to be elevated in participants with decreased renal function, 27 associated with cardiovascular events in a cohort of patients with type 1 diabetes and diabetes nephropathy, 28 and suggested as a marker to be used in risk stratification of patients at risk of acute coronary syndrome. 29 PlGF has also been shown to be associated with albuminuria in patients with chronic kidney disease 30 ; however, we are aware of no previous study reporting these associations in participants with normal renal function. GDF-15 is also known as macrophage inhibitory cytokine-1 (MIC-1), which regulates body weight and has been associated with cancer, inflammation and cardiovascular diseases.
31 GDF-15 has been shown to be associated with carotid artery thickening and mortality in patients undergoing haemodialysis 32 and with incident heart failure and cardiovascular events in the community. 33 Higher levels of GDF-15 have also been associated with a decline in kidney function and cardiovascular events in participants with type 1 diabetes 34 and with progression in the albuminuria stage in patients with type 2 diabetes. 35 We are aware of no previous study that has reported an association between GDF-15 and albuminuria in the absence of diabetes. Whether GDF-15 portrays the inflammatory activity, disturbed glucometabolic effects, or both, that predispose to, or parallel, the development of microalbuminuria, is yet to be determined.
Vascular smooth muscle cells in atherosclerotic plaques have been shown to express U-PAR. 36, 37 U-PAR has also been suggested to be a marker of glomerulosclerosis and podocyte injury. 38 As such, U-PAR has been thoroughly researched for its importance in chronic kidney disease and specifically for its association with albuminuria. 39 Our study confirms and extends our knowledge of plasma U-PAR as a biomarker of kidney damage.
It is well established that the kallikrein-kinin system has substantial impacts on cardiovascular and kidney pathology, specifically arterial function and tubular reabsorption; 40 however, we have not been able to find any study specifically targeting hK11, making the present findings of interest for future investigations.
Although we cannot deem the present observational findings as causal, the fact that all five replicated proteins were associated with ACR in participants without diabetes and that three of them were associated with ACR in participants with normal renal function indicates that the biological pathway involving some of these cardiovascular proteins take place prior to, and probably parallel to, the development of diabetic nephropathy.
Albuminuria is closely associated with prevalent cardiovascular disease, cardiovascular risk factors such as diabetes and hypertension, and has also been shown to mirror the filtration of proteins to primary urine, 41 tubular reabsorption 42 and endothelial function. 8, 9 All models in the present study were adjusted for prevalent cardiovascular disease, cardiovascular risk factors, antihypertensive treatment and GFR at the baseline investigation, arguing against these factors as main pathways explaining our findings.
There is growing recognition of the importance of the detrimental interaction between kidney function and the cardiovascular system. However, there has been little advancement in the study of biomarkers that mirror this interplay. Albuminuria and creatinine-based estimations of GFR are currently used in clinical practice, despite the fact that they are influenced by body size, race, sex and lifestyle, and have limited sensitivity and specificity. Our data suggest that largescale proteomics may be a promising way to discover novel biomarkers mirroring both kidney and cardiovascular disease that ultimately could be used for improved risk prediction, diagnosis and monitoring of patients, as well as leads in the development of novel drugs for cardiovascular prevention and reno-protection.
The strengths of our investigation include the discovery replication approach with validation of findings in an independent cohort, the use of a state-of-the art proteomics chip and the detailed characterization of study participants.
Limitations include the unknown generalizability to other age and ethnic groups and that there may be healthy cohort effects at play in population-based invited investigations of elderly participants. Our study was based on single assessments of creatinine, albuminuria and the proteomic cardiovascular chip; in PIVUS there were about 5 years between the collection of the plasma samples when the protein measurements were performed and the albuminuria measurements. Potential misclassification due to these limitations may result in more conservative estimates and it is probable that additional findings from the discovery phase in ULSAM would have been replicated in PIVUS if the proteomic data and albuminuria data had been available at the same investigation. Given the 5-year time lag in the replication cohort, it is possible that more stable proteins were favoured over less stable proteins in our statistical analyses. Differences in age, sex distribution and the prevalence of cardiovascular disease in the two samples may have diluted the associations further. Additional replications of the findings from the discovery analyses are warranted. Participants with diabetes, cardiovascular disease or chronic kidney disease in the two cohorts were too few to make analyses in these subgroups meaningful.
Using a multiplex proteomics approach, we discovered and replicated the association between five circulating cardiovascular-related proteins (TIM-1, PlGF, GDF-15, U-PAR and hK11) and ACR in two independent cohorts. Our findings suggested that albuminuria mirrors a complex cardiovascular pathology and put forward large-scale proteomics as a promising approach to explore novel aspects of the detrimental interplay between kidney function and the cardiovascular system.
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